Conference report: WHO meeting summary on mRNA-based tuberculosis vaccine development
•The TB vaccine development pipeline moves slowly and includes few candidates.•TB progression-associated candidate antigens have recently been identified.•Investigation to identify vaccine-induced correlates of protection against TB is underway.•The mRNA platform may accelerate screening and manufac...
Gespeichert in:
| Veröffentlicht in: | Vaccine 2023-11, Vol.41 (48), p.7060-7066 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 7066 |
|---|---|
| container_issue | 48 |
| container_start_page | 7060 |
| container_title | Vaccine |
| container_volume | 41 |
| creator | Looney, Monika M. Hatherill, Mark Musvosvi, Munyaradzi Flynn, JoAnne Kagina, Benjamin M Frick, Mike Kafuko, Zacharia Schmidt, Alex Southern, James Wilder-Smith, Annelies Tippoo, Patrick Paradkar, Vikram Popadić, Dušan Scriba, Thomas J. Hanekom, Willem Giersing, Brigitte |
| description | •The TB vaccine development pipeline moves slowly and includes few candidates.•TB progression-associated candidate antigens have recently been identified.•Investigation to identify vaccine-induced correlates of protection against TB is underway.•The mRNA platform may accelerate screening and manufacturing of new TB vaccines.•Transparency and community engagement are critical for mRNA vaccine acceptability.•Capacity building in lesser resourced regions may improve equitable TB vaccine access.
Tuberculosis (TB) is a global health emergency. Across the globe, approximately 2 billion people are currently infected with Mycobacterium tuberculosis (Mtb), and of those, 5–10% may progress to become ill and potentially transmit the bacterium. In 2021, nearly 10.6 million people developed TB disease and 1.6 million died. There is an urgent need for accelerated development of new TB-focused interventions, in particular, improved TB vaccines. However, progress in developing highly effective TB vaccines has been slow and is chronically under-resourced. The mRNA vaccine platform may offer an opportunity to accelerate development of new TB vaccines.
In April 2023, the World Health Organization convened global experts to discuss the feasibility and potential value of mRNA-based vaccines for TB. Here we report on meeting deliberations related to the current TB vaccine pipeline and potential novel antigens, the status of efforts to identify correlates of protection, potential clinical development strategies and considerations for community acceptance of new TB vaccines based on this relatively new platform. The role of industry collaborations, ethics, social science, and responsibility to the global community regarding transparency and manufacturing capacity building were discussed through expert presentations and panel sessions. The overall conclusion of the meeting is that mRNA-based vaccines constitute a potentially powerful new tool for reducing the global burden of TB. |
| doi_str_mv | 10.1016/j.vaccine.2023.10.026 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3154161099</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X23012094</els_id><sourcerecordid>2891448058</sourcerecordid><originalsourceid>FETCH-LOGICAL-c421t-534e8be5bf13c48ad9cffa84115455393824b136f3e8add38cd6bbf0edb5cb523</originalsourceid><addsrcrecordid>eNqFkV9rFDEUxYModq1-BCXgiy-zzc2f2YwvUhZtC8VCadG3MEnuSJaZyZrMLPjtzbBbH3zpU-Dkd09uziHkPbA1MKgvdutD61wYcc0ZF0VbM16_ICvQG1FxBfolWRVFVhLYzzPyJucdY0wJaF6TM7HRG85ArMjjNo4dJhwd0oT7mKbP9Mf1HR0QpzD-onkehjb9oXGkw_33y8q2GT2dZovJzX3MIdPTHtTjAfu4H3Cc3pJXXdtnfHc6z8njt68P2-vq9u7qZnt5WznJYaqUkKgtKtuBcFK3vnFd12oJoKRSohGaSwui7gSWSy-087W1HUNvlbOKi3Py6ei7T_H3jHkyQ8gO-74dMc7ZiGIENbCmeRblWgOXsuabgn78D93FOY3lI4VqQErNlC6UOlIuxZwTdmafwpKVAWaWiszOnKIxS0WLXAopcx9O7rMd0P-beuqkAF-OAJbkDgGTyS4sBfmQ0E3Gx_DME38BrfKkUg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2891448058</pqid></control><display><type>article</type><title>Conference report: WHO meeting summary on mRNA-based tuberculosis vaccine development</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Looney, Monika M. ; Hatherill, Mark ; Musvosvi, Munyaradzi ; Flynn, JoAnne ; Kagina, Benjamin M ; Frick, Mike ; Kafuko, Zacharia ; Schmidt, Alex ; Southern, James ; Wilder-Smith, Annelies ; Tippoo, Patrick ; Paradkar, Vikram ; Popadić, Dušan ; Scriba, Thomas J. ; Hanekom, Willem ; Giersing, Brigitte</creator><creatorcontrib>Looney, Monika M. ; Hatherill, Mark ; Musvosvi, Munyaradzi ; Flynn, JoAnne ; Kagina, Benjamin M ; Frick, Mike ; Kafuko, Zacharia ; Schmidt, Alex ; Southern, James ; Wilder-Smith, Annelies ; Tippoo, Patrick ; Paradkar, Vikram ; Popadić, Dušan ; Scriba, Thomas J. ; Hanekom, Willem ; Giersing, Brigitte</creatorcontrib><description>•The TB vaccine development pipeline moves slowly and includes few candidates.•TB progression-associated candidate antigens have recently been identified.•Investigation to identify vaccine-induced correlates of protection against TB is underway.•The mRNA platform may accelerate screening and manufacturing of new TB vaccines.•Transparency and community engagement are critical for mRNA vaccine acceptability.•Capacity building in lesser resourced regions may improve equitable TB vaccine access.
Tuberculosis (TB) is a global health emergency. Across the globe, approximately 2 billion people are currently infected with Mycobacterium tuberculosis (Mtb), and of those, 5–10% may progress to become ill and potentially transmit the bacterium. In 2021, nearly 10.6 million people developed TB disease and 1.6 million died. There is an urgent need for accelerated development of new TB-focused interventions, in particular, improved TB vaccines. However, progress in developing highly effective TB vaccines has been slow and is chronically under-resourced. The mRNA vaccine platform may offer an opportunity to accelerate development of new TB vaccines.
In April 2023, the World Health Organization convened global experts to discuss the feasibility and potential value of mRNA-based vaccines for TB. Here we report on meeting deliberations related to the current TB vaccine pipeline and potential novel antigens, the status of efforts to identify correlates of protection, potential clinical development strategies and considerations for community acceptance of new TB vaccines based on this relatively new platform. The role of industry collaborations, ethics, social science, and responsibility to the global community regarding transparency and manufacturing capacity building were discussed through expert presentations and panel sessions. The overall conclusion of the meeting is that mRNA-based vaccines constitute a potentially powerful new tool for reducing the global burden of TB.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2023.10.026</identifier><identifier>PMID: 37872013</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Adults ; Antigens ; bacteria ; Capacity development ; COVID-19 vaccines ; Development strategies ; Disease prevention ; Disease transmission ; ethics ; Fatalities ; Global health ; Humans ; Immunization ; Immunology ; industry ; Infections ; Infectious diseases ; Low income groups ; mRNA ; Mycobacterium tuberculosis ; Mycobacterium tuberculosis - genetics ; Pandemics ; people ; Public health ; R&D ; Research & development ; RNA, Messenger - genetics ; Social sciences ; Technology transfer ; Teenagers ; Tuberculosis ; Tuberculosis Vaccines - genetics ; Vaccine development ; Vaccines ; World Health Organization</subject><ispartof>Vaccine, 2023-11, Vol.41 (48), p.7060-7066</ispartof><rights>2023</rights><rights>Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.</rights><rights>2023. The Authors</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c421t-534e8be5bf13c48ad9cffa84115455393824b136f3e8add38cd6bbf0edb5cb523</cites><orcidid>0000-0002-3295-5528</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0264410X23012094$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37872013$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Looney, Monika M.</creatorcontrib><creatorcontrib>Hatherill, Mark</creatorcontrib><creatorcontrib>Musvosvi, Munyaradzi</creatorcontrib><creatorcontrib>Flynn, JoAnne</creatorcontrib><creatorcontrib>Kagina, Benjamin M</creatorcontrib><creatorcontrib>Frick, Mike</creatorcontrib><creatorcontrib>Kafuko, Zacharia</creatorcontrib><creatorcontrib>Schmidt, Alex</creatorcontrib><creatorcontrib>Southern, James</creatorcontrib><creatorcontrib>Wilder-Smith, Annelies</creatorcontrib><creatorcontrib>Tippoo, Patrick</creatorcontrib><creatorcontrib>Paradkar, Vikram</creatorcontrib><creatorcontrib>Popadić, Dušan</creatorcontrib><creatorcontrib>Scriba, Thomas J.</creatorcontrib><creatorcontrib>Hanekom, Willem</creatorcontrib><creatorcontrib>Giersing, Brigitte</creatorcontrib><title>Conference report: WHO meeting summary on mRNA-based tuberculosis vaccine development</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>•The TB vaccine development pipeline moves slowly and includes few candidates.•TB progression-associated candidate antigens have recently been identified.•Investigation to identify vaccine-induced correlates of protection against TB is underway.•The mRNA platform may accelerate screening and manufacturing of new TB vaccines.•Transparency and community engagement are critical for mRNA vaccine acceptability.•Capacity building in lesser resourced regions may improve equitable TB vaccine access.
Tuberculosis (TB) is a global health emergency. Across the globe, approximately 2 billion people are currently infected with Mycobacterium tuberculosis (Mtb), and of those, 5–10% may progress to become ill and potentially transmit the bacterium. In 2021, nearly 10.6 million people developed TB disease and 1.6 million died. There is an urgent need for accelerated development of new TB-focused interventions, in particular, improved TB vaccines. However, progress in developing highly effective TB vaccines has been slow and is chronically under-resourced. The mRNA vaccine platform may offer an opportunity to accelerate development of new TB vaccines.
In April 2023, the World Health Organization convened global experts to discuss the feasibility and potential value of mRNA-based vaccines for TB. Here we report on meeting deliberations related to the current TB vaccine pipeline and potential novel antigens, the status of efforts to identify correlates of protection, potential clinical development strategies and considerations for community acceptance of new TB vaccines based on this relatively new platform. The role of industry collaborations, ethics, social science, and responsibility to the global community regarding transparency and manufacturing capacity building were discussed through expert presentations and panel sessions. The overall conclusion of the meeting is that mRNA-based vaccines constitute a potentially powerful new tool for reducing the global burden of TB.</description><subject>Adults</subject><subject>Antigens</subject><subject>bacteria</subject><subject>Capacity development</subject><subject>COVID-19 vaccines</subject><subject>Development strategies</subject><subject>Disease prevention</subject><subject>Disease transmission</subject><subject>ethics</subject><subject>Fatalities</subject><subject>Global health</subject><subject>Humans</subject><subject>Immunization</subject><subject>Immunology</subject><subject>industry</subject><subject>Infections</subject><subject>Infectious diseases</subject><subject>Low income groups</subject><subject>mRNA</subject><subject>Mycobacterium tuberculosis</subject><subject>Mycobacterium tuberculosis - genetics</subject><subject>Pandemics</subject><subject>people</subject><subject>Public health</subject><subject>R&D</subject><subject>Research & development</subject><subject>RNA, Messenger - genetics</subject><subject>Social sciences</subject><subject>Technology transfer</subject><subject>Teenagers</subject><subject>Tuberculosis</subject><subject>Tuberculosis Vaccines - genetics</subject><subject>Vaccine development</subject><subject>Vaccines</subject><subject>World Health Organization</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkV9rFDEUxYModq1-BCXgiy-zzc2f2YwvUhZtC8VCadG3MEnuSJaZyZrMLPjtzbBbH3zpU-Dkd09uziHkPbA1MKgvdutD61wYcc0ZF0VbM16_ICvQG1FxBfolWRVFVhLYzzPyJucdY0wJaF6TM7HRG85ArMjjNo4dJhwd0oT7mKbP9Mf1HR0QpzD-onkehjb9oXGkw_33y8q2GT2dZovJzX3MIdPTHtTjAfu4H3Cc3pJXXdtnfHc6z8njt68P2-vq9u7qZnt5WznJYaqUkKgtKtuBcFK3vnFd12oJoKRSohGaSwui7gSWSy-087W1HUNvlbOKi3Py6ei7T_H3jHkyQ8gO-74dMc7ZiGIENbCmeRblWgOXsuabgn78D93FOY3lI4VqQErNlC6UOlIuxZwTdmafwpKVAWaWiszOnKIxS0WLXAopcx9O7rMd0P-beuqkAF-OAJbkDgGTyS4sBfmQ0E3Gx_DME38BrfKkUg</recordid><startdate>20231122</startdate><enddate>20231122</enddate><creator>Looney, Monika M.</creator><creator>Hatherill, Mark</creator><creator>Musvosvi, Munyaradzi</creator><creator>Flynn, JoAnne</creator><creator>Kagina, Benjamin M</creator><creator>Frick, Mike</creator><creator>Kafuko, Zacharia</creator><creator>Schmidt, Alex</creator><creator>Southern, James</creator><creator>Wilder-Smith, Annelies</creator><creator>Tippoo, Patrick</creator><creator>Paradkar, Vikram</creator><creator>Popadić, Dušan</creator><creator>Scriba, Thomas J.</creator><creator>Hanekom, Willem</creator><creator>Giersing, Brigitte</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>7S9</scope><scope>L.6</scope><orcidid>https://orcid.org/0000-0002-3295-5528</orcidid></search><sort><creationdate>20231122</creationdate><title>Conference report: WHO meeting summary on mRNA-based tuberculosis vaccine development</title><author>Looney, Monika M. ; Hatherill, Mark ; Musvosvi, Munyaradzi ; Flynn, JoAnne ; Kagina, Benjamin M ; Frick, Mike ; Kafuko, Zacharia ; Schmidt, Alex ; Southern, James ; Wilder-Smith, Annelies ; Tippoo, Patrick ; Paradkar, Vikram ; Popadić, Dušan ; Scriba, Thomas J. ; Hanekom, Willem ; Giersing, Brigitte</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c421t-534e8be5bf13c48ad9cffa84115455393824b136f3e8add38cd6bbf0edb5cb523</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Adults</topic><topic>Antigens</topic><topic>bacteria</topic><topic>Capacity development</topic><topic>COVID-19 vaccines</topic><topic>Development strategies</topic><topic>Disease prevention</topic><topic>Disease transmission</topic><topic>ethics</topic><topic>Fatalities</topic><topic>Global health</topic><topic>Humans</topic><topic>Immunization</topic><topic>Immunology</topic><topic>industry</topic><topic>Infections</topic><topic>Infectious diseases</topic><topic>Low income groups</topic><topic>mRNA</topic><topic>Mycobacterium tuberculosis</topic><topic>Mycobacterium tuberculosis - genetics</topic><topic>Pandemics</topic><topic>people</topic><topic>Public health</topic><topic>R&D</topic><topic>Research & development</topic><topic>RNA, Messenger - genetics</topic><topic>Social sciences</topic><topic>Technology transfer</topic><topic>Teenagers</topic><topic>Tuberculosis</topic><topic>Tuberculosis Vaccines - genetics</topic><topic>Vaccine development</topic><topic>Vaccines</topic><topic>World Health Organization</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Looney, Monika M.</creatorcontrib><creatorcontrib>Hatherill, Mark</creatorcontrib><creatorcontrib>Musvosvi, Munyaradzi</creatorcontrib><creatorcontrib>Flynn, JoAnne</creatorcontrib><creatorcontrib>Kagina, Benjamin M</creatorcontrib><creatorcontrib>Frick, Mike</creatorcontrib><creatorcontrib>Kafuko, Zacharia</creatorcontrib><creatorcontrib>Schmidt, Alex</creatorcontrib><creatorcontrib>Southern, James</creatorcontrib><creatorcontrib>Wilder-Smith, Annelies</creatorcontrib><creatorcontrib>Tippoo, Patrick</creatorcontrib><creatorcontrib>Paradkar, Vikram</creatorcontrib><creatorcontrib>Popadić, Dušan</creatorcontrib><creatorcontrib>Scriba, Thomas J.</creatorcontrib><creatorcontrib>Hanekom, Willem</creatorcontrib><creatorcontrib>Giersing, Brigitte</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>AGRICOLA</collection><collection>AGRICOLA - Academic</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Looney, Monika M.</au><au>Hatherill, Mark</au><au>Musvosvi, Munyaradzi</au><au>Flynn, JoAnne</au><au>Kagina, Benjamin M</au><au>Frick, Mike</au><au>Kafuko, Zacharia</au><au>Schmidt, Alex</au><au>Southern, James</au><au>Wilder-Smith, Annelies</au><au>Tippoo, Patrick</au><au>Paradkar, Vikram</au><au>Popadić, Dušan</au><au>Scriba, Thomas J.</au><au>Hanekom, Willem</au><au>Giersing, Brigitte</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Conference report: WHO meeting summary on mRNA-based tuberculosis vaccine development</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2023-11-22</date><risdate>2023</risdate><volume>41</volume><issue>48</issue><spage>7060</spage><epage>7066</epage><pages>7060-7066</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><abstract>•The TB vaccine development pipeline moves slowly and includes few candidates.•TB progression-associated candidate antigens have recently been identified.•Investigation to identify vaccine-induced correlates of protection against TB is underway.•The mRNA platform may accelerate screening and manufacturing of new TB vaccines.•Transparency and community engagement are critical for mRNA vaccine acceptability.•Capacity building in lesser resourced regions may improve equitable TB vaccine access.
Tuberculosis (TB) is a global health emergency. Across the globe, approximately 2 billion people are currently infected with Mycobacterium tuberculosis (Mtb), and of those, 5–10% may progress to become ill and potentially transmit the bacterium. In 2021, nearly 10.6 million people developed TB disease and 1.6 million died. There is an urgent need for accelerated development of new TB-focused interventions, in particular, improved TB vaccines. However, progress in developing highly effective TB vaccines has been slow and is chronically under-resourced. The mRNA vaccine platform may offer an opportunity to accelerate development of new TB vaccines.
In April 2023, the World Health Organization convened global experts to discuss the feasibility and potential value of mRNA-based vaccines for TB. Here we report on meeting deliberations related to the current TB vaccine pipeline and potential novel antigens, the status of efforts to identify correlates of protection, potential clinical development strategies and considerations for community acceptance of new TB vaccines based on this relatively new platform. The role of industry collaborations, ethics, social science, and responsibility to the global community regarding transparency and manufacturing capacity building were discussed through expert presentations and panel sessions. The overall conclusion of the meeting is that mRNA-based vaccines constitute a potentially powerful new tool for reducing the global burden of TB.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>37872013</pmid><doi>10.1016/j.vaccine.2023.10.026</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0002-3295-5528</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0264-410X |
| ispartof | Vaccine, 2023-11, Vol.41 (48), p.7060-7066 |
| issn | 0264-410X 1873-2518 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3154161099 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Adults Antigens bacteria Capacity development COVID-19 vaccines Development strategies Disease prevention Disease transmission ethics Fatalities Global health Humans Immunization Immunology industry Infections Infectious diseases Low income groups mRNA Mycobacterium tuberculosis Mycobacterium tuberculosis - genetics Pandemics people Public health R&D Research & development RNA, Messenger - genetics Social sciences Technology transfer Teenagers Tuberculosis Tuberculosis Vaccines - genetics Vaccine development Vaccines World Health Organization |
| title | Conference report: WHO meeting summary on mRNA-based tuberculosis vaccine development |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T14%3A23%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Conference%20report:%20WHO%20meeting%20summary%20on%20mRNA-based%20tuberculosis%20vaccine%20development&rft.jtitle=Vaccine&rft.au=Looney,%20Monika%20M.&rft.date=2023-11-22&rft.volume=41&rft.issue=48&rft.spage=7060&rft.epage=7066&rft.pages=7060-7066&rft.issn=0264-410X&rft.eissn=1873-2518&rft_id=info:doi/10.1016/j.vaccine.2023.10.026&rft_dat=%3Cproquest_cross%3E2891448058%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2891448058&rft_id=info:pmid/37872013&rft_els_id=S0264410X23012094&rfr_iscdi=true |